Detailed analysis of protein expression market

Protein expression is a process that controls the synthesis, regulation, and modification of proteins in cells. Recombinant proteins can be expressed in various host systems thanks to protein expression, which is a crucial proteomic component. Protein synthesis and control are governed by a functional requirement dependent on the host cell. Three steps, including transcription, translation, and post-translational modification, are involved in protein expression.

The market worth of protein expression in 2021 was USD 2.45 billion, and by 2030 it will be worth USD 6.47 billion, growing at an 11.4% CAGR during 2021-2030.

This market is growing due to factors like expanding biotechnology and pharmaceutical sectors, rising recombinant-based protein expression usage, and rising public and private support via initiatives and financing. The high cost of the equipment and chemicals used in protein expression will impede the market’s expansion.

Market Dynamics

Drivers

The rising rate of chronic diseases like cancer, heart disease, stroke, diabetes, arthritis, and others drives the expansion of the protein expression market. Biologics, which include vaccinations, blood components, and therapeutic proteins, are used to treat certain disorders. As a result, the market is expanding due to the increasing demand for protein biologics. Furthermore, the market is expanding by increasing research in proteomics and biotechnology. Growing academic activities for novel protein therapy development have presented lucrative potential possibilities to the Asia Pacific market.

Restraints

The key factors restricting the expansion of the global sector include poor R&D spending, a lack of standardization, a lower rate of prevailing professionals, and the excessive expense of proteomics research.

Opportunity

• The rise in the rate of chronic diseases will drive the market’s expansion. The market size will expand due to the rising need for protein biologics.
• The expansion of emerging countries and the advent of microfluidics have contributed significantly to progress, increasing opportunities for the market for protein expression systems to expand in the coming years.

Market Segmentation

Expression system insights

In 2021, the prokaryotic sector held the highest share of more than 40.0% as it is generally simpler to handle and serves important research reasons. Due to its advantageous traits, including its ability to produce large quantities of recombinant proteins quickly and inexpensively, the market segment will maintain its position during the projection period.

Product Insights

The reagents segment maintained the largest market position in 2021, with 40.0% of the share. Thermo Fisher Scientific and Agilent Technologies, Inc. are examples of established market participants. To meet the unique requirements of transfection and optimize the circumstances of cell culture, the firms provide a wide selection of transfection reagents.

From 2022 to 2030, the services market will grow at a CAGR of 12.1%. The expansion is due to the growing outsourcing of protein creation and expression by pharmaceutical and biotech firms to antibody production businesses in order to support the development of tailored assays and the discovery of therapeutic antibodies.

Application Insights

In the year 2021, the therapeutic segment held the largest market with a revenue share of 50.0%, as protein therapeutics offer several advantages over other pharmaceuticals. Due to their adaptability, they provide a more successful course of therapy and have a reduced likelihood of adverse consequences. It can also serve as replacement therapy when a gene defect prevents the body from producing enough functional proteins.

End-User Insights

Due to the widespread usage of cultured cells for creating therapies and tailored medications, the pharmaceutical and biotechnology firms category had the highest revenue share of almost 45.0% in 2021. The pharmaceutical industry’s expanding inventive usage of proteins drives the market. The companies combine already-existing proteins with genetic variants and entirely new protein designs to produce a greater value in therapeutics and protein stability.

Regional Insights

In 2021, North America led the entire regional market with the biggest share of 40.0%. This sizeable market share is due to important competitors in the area, rising R&D funding, and robust biosimilar pipelines. 

Due to the increasing use of protein expression in numerous applications, notably in India and China, Asia Pacific will have the quickest growth. The Asia Pacific market has also benefited from the expanding emphasis on proteomics and genomics research and rising academic institution initiatives for novel protein therapy development.

Key Players 

• Takara Bio Inc
• New England Biolabs
• Agilent Technologies Inc.
• Merck KGaA
• BECTON, DICKINSON AND COMPANY
• LifeSensors Inc.
• Promega Corporation
• BIO-RAD LABORATORIES, INC.
• GenScript Biotech Corporation
• QIAGEN NV.
• Oxford Expression Technologies Ltd.
• THERMO FISHER SCIENTIFIC, INC.
• Synthetic Genomics Inc.

The market worth of protein expression in 2021 was USD 2.45 billion, and by 2030 it will be worth USD 6.47 billion, growing at an 11.4% CAGR during 2021-2030. The main drivers of the market’s expansion are the rising incidence of chronic diseases, expanding demand for protein biologics, and a rise in global healthcare spending. Additionally, the expansion of the field of proteomics and the rise in R&D efforts by the pharmaceutical industry in developing regions present potential for the market.